Samsung Biologics is facing its first general strike since its founding, a significant event that has already halted production of key biopharmaceuticals and resulted in an estimated loss of ₩150 billion.
The immediate trigger was a partial strike in the materials subdivision department from April 28-30. This initial action created a critical bottleneck in the supply of raw materials, making normal production impossible and leading to the shutdown of several manufacturing batches, including treatments for cancer and HIV. This illustrates how a targeted disruption in a complex manufacturing process can quickly cascade into a full-scale operational crisis.
However, the roots of this conflict run deeper. The strike is the culmination of months of failed negotiations. The union demanded a 14% wage increase and substantial bonuses, a stark contrast to the company's offer of a 6.2% total increase. This wide gap was heavily influenced by an external benchmark: in September 2025, competitor SK Hynix agreed to a landmark deal linking bonuses directly to operating profits. This set a new precedent in the industry, raising the expectations of workers at other major Korean corporations, including Samsung.
Adding another layer of complexity is the geopolitical landscape. The passage of the US BIOSECURE Act in late 2025 restricts federal funding for services from certain Chinese biotech companies. This has significantly increased the strategic importance of non-Chinese CDMOs like Samsung Biologics, making them critical nodes in the global pharmaceutical supply chain. Consequently, the market's sensitivity to any operational instability—like this strike—is amplified. The disruption is no longer just a financial issue; it poses a direct threat to process integrity, which could attract scrutiny from regulators like the FDA and damage the company's reputation for reliability.
- Batch: A specific quantity of a drug or other material that is intended to have a uniform character and quality, and is produced during a single manufacturing cycle.
- CDMO (Contract Development and Manufacturing Organization): A company that provides comprehensive services from drug development through drug manufacturing on a contract basis to the pharmaceutical industry.
- BIOSECURE Act: A US law aimed at preventing certain foreign biotechnology companies considered a threat to national security from accessing US federal funding and contracts.